Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488825 | 0.91 | HPGD (0.36) | HPGDPTPRBHSD17B10 | |
| SCHEMBL6499126 | 0.70 | DRD2 (0.39) | HPGDPTPRBHSD17B10 | |
| SCHEMBL13351404 | 0.67 | HSD17B10 (0.48) | HPGDPTPRBHSD17B10 | |
| SCHEMBL6600598 | 0.66 | HSD17B10 (0.60) | HPGDPTPRBHSD17B10 | |
| SCHEMBL6488038 | 0.66 | KMT2A (0.47) | — | |
| SCHEMBL14625056 | 0.60 | ALDH1A1 (0.42) | HPGDHSD17B10 | |
| SCHEMBL6495773 | 0.60 | HSD17B10 (0.49) | HPGDPTPRBHSD17B10 | |
| SCHEMBL15463134 | 0.60 | HTT (0.41) | HPGDHSD17B10 | |
| SCHEMBL27523775 | 0.59 | TSHR (0.54) | HPGDHSD17B10 | |
| SCHEMBL16789819 | 0.59 | HSD17B10 (0.47) | HPGDPTPRBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | HPGD 2381/4885PTPRB 1163/4885HSD17B10 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.